{"body":"<p><strong>A5.11 Primaquine<\/strong><\/p>&#13;\n&#13;\n<p><em>Therapeutic indications<\/em><\/p>&#13;\n&#13;\n<p>Primaquine is indicated for radical cure of P. <em>vivax<\/em> or P. <em>ovale<\/em> malaria; for presumptive anti-relapse therapy (terminal prophylaxis) in people extensively exposed to P. <em>vivax<\/em> or P. <em>ovale<\/em>; to reduce onward transmission of P. <em>falciparum<\/em> malaria in programmes to eliminate P. <em>falciparum<\/em> malaria and in areas threatened by resistance of P. <em>falciparum<\/em> to artemisinins; and as an alternative for primary prophylaxis against all malaria species.<\/p>&#13;\n&#13;\n<p>Except in primary prophylaxis, primaquine is used in conjunction with an effective blood schizonticide: either ACT, or chloroquine for vivax or ovale malaria.<\/p>&#13;\n&#13;\n<p><strong>Structure and mechanism of action <\/strong><\/p>&#13;\n&#13;\n<p>Primaquine is an 8-aminoquinoline, which is highly active against the exoerythrocytic forms (hypnozoites) and the sexual stages of malaria parasites (gametocytes). It has weak activity against the asexual blood stages of P. <em>vivax<\/em> and has negligible activity against P. <em>falciparum<\/em>. Although P. <em>falciparum<\/em> gametocyte clearance takes days, gametocytes are sterilized within hours; therefore, the effect of primaquine on oocyst and sporozoite formation (and thus onward transmission of the treated infection) precedes its effect on gametocyte carriage (1).<\/p>&#13;\n&#13;\n<p><img alt=\"\" src=\"data:image\/gif;base64,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\" style=\"height=624;width=1024\" \/><\/p>&#13;\n&#13;\n<p><strong>Molecular mass: 259.4<\/strong><\/p>&#13;\n&#13;\n<p>Hepatic metabolism of primaquine produces reactive intermediate metabolites that generate toxic intracellular oxidative species. The parent compound itself is relatively inactive. The precise mechanism of action of primaquine is not fully understood, but it is thought that the reactive intermediates disrupt the metabolic processes of plasmodial mitochondria and interfere with electron transport in the parasite (2, 3). There is no evidence for acquired resistance to its hypnozoitocidal or gametocytocidal activities.<\/p>&#13;\n&#13;\n<p><strong>Pharmacokinetics<\/strong><\/p>&#13;\n&#13;\n<p>Primaquine is rapidly absorbed from the gastrointestinal tract, reaching peak concentrations within 1\u20134 h, with a bioavailability of about 96% (4). Primaquine is biotransformed by two main routes: by monoamine oxidase to the predominant, but inactive, metabolite carboxyprimaquine, which is relatively slowly eliminated; and via CYP2C19, CYP2D6 and CYP3A4 in the liver, which generate the reactive intermediates responsible for antimalarial effects and haemolytic toxicity (5\u20137). Genetic polymorphisms that decrease CYP2D6 enzyme activity reduce bioactivation of primaquine and may result in treatment failure. Primaquine is extensively distributed in the body. About 75% of primaquine in plasma is bound to proteins, and high concentrations occur in erythrocytes. Primaquine crosses the placenta, but it is uncertain whether significant amounts occur in breast milk (8).<\/p>&#13;\n&#13;\n<p>Both primaquine and carboxyprimaquine are excreted mainly through the biliary tract and can be found in faeces within 24 h of administration (8). Primaquine is also excreted in the urine as unchanged drug. Conflicting results have been reported on the effects of gender on the disposition of primaquine, some studies reporting increased exposure and hence greater side-effects in women and others reporting no effect of gender (9\u201311). In view of the relatively small samples in each of these studies, the findings should be interpreted cautiously. The pharmacokinetics of a single oral dose of 15 mg did not appear to be altered in patients with severely impaired renal function and end-stage renal dysfunction (12).<\/p>&#13;\n&#13;\n<p>The pharmacokinetic parameters of primaquine are summarized in Table A5.11 (4, 7, 9\u201318).<\/p>&#13;\n&#13;\n<p><strong>Table A5.11. pharmacokinetic parameters of primaquine and carboxyprimaquine in studies in healthy volunteers and patients (range of mean or median values reported). <\/strong><\/p>&#13;\n&#13;\n<p><img alt=\"\" src=\"data:image\/gif;base64,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\" style=\"height=304;width=1024\" \/><\/p>&#13;\n&#13;\n<p><strong>Safety <\/strong><\/p>&#13;\n&#13;\n<p><em><strong>Adverse events <\/strong><\/em><\/p>&#13;\n&#13;\n<p>While primaquine is generally well tolerated, it may cause dose-related gastrointestinal discomfort, including abdominal pain, nausea and vomiting (19\u201322). Administration with food improves tolerability. Hypertension and cardiac arrhythmia have been reported rarely. The most important adverse effect is haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, and the degree of haemolysis is proportional to the dose, duration of exposure, and degree of G6PD deficiency. Leukopenia, methaemoglobinaemia with cyanosis and granulocytopenia may also occur. Fortunately, primaquine is eliminated rapidly, so that haemolysis stops once the drug is stopped. Patients should discontinue primaquine if they pass red or black urine, or have symptomatic anaemia.<\/p>&#13;\n&#13;\n<p><em><strong>Contraindications <\/strong><\/em><\/p>&#13;\n&#13;\n<p>Primaquine is contraindicated in patients with known hypersensitivity to primaquine or related compounds and in patients with severe G6PD deficiency or severe nicotinamide adenine dinucleotide (NADH) methaemoglobin reductase deficiency. Primaquine crosses the placenta and may cause haemolysis in a G6PD-deficient fetus; it is therefore not recommended for use during pregnancy or during breastfeeding unless the G6PD status of the infant is known. Use of primaquine in infants &lt; 6 months is not advised because of lack of data on its safety.<\/p>&#13;\n&#13;\n<p><em><strong>Caution<\/strong><\/em><\/p>&#13;\n&#13;\n<p>The different variants of G6PD deficiency are associated with significantly different risks for haemolysis. The African A\u2013 variant is at the less severe end of the spectrum of severity, and the Mediterranean variant (which predominates in southern Europe, the Middle East and Central Asia) is at the more severe end (23). Administration of a single dose of 0.25 mg base\/kg bw as a gametocytocide is considered to confer no significant haemolytic risk in people with any of the variants; therefore, testing for GDPD deficiency is not required before this single dose administration. The regimens necessary for radical cure may, however, cause significant, occasionally life-threatening haemolyisis in G6PD-deficient patients; therefore, testing for G6PD deficiency is recommended before radical cure regimens. Unfortunately, testing is not widely available, so an individual decision on whether to prescribe radical a curative regimen depends on an assessment of the potential risks of haemolytic toxicity and the benefits of preventing relapse. This assessment must be based on knowledge of the prevalence and severity of G6PD deficiency in the patient\u2019s ethnic group and the risks and impact of vivax relapse in the area. Caution is also advised in treating patients with systemic diseases associated with an increased risk for granulocytopenia, such as rheumatoid arthritis and systemic lupus erythematosus.<\/p>&#13;\n&#13;\n<p><em><strong>Drug interactions<\/strong><\/em><\/p>&#13;\n&#13;\n<p>See Table A5.14.<\/p>&#13;\n&#13;\n<p><strong>Dose optimization <\/strong><\/p>&#13;\n&#13;\n<p>The dosages recommended for radical cure of <em>P. vivax or P. ovale<\/em> malaria, presumptive anti-relapse therapy (0.25 mg base\/kg bw per day for 14 days for \u201ctemperate strain infections\u201d and 0.50 mg base\/kg bw per day for 14 days for tropical, frequently relapsing infections) and primary prophylaxis (0.5 mg\/kg bw base up to maximum oral dose of 30 mg daily) remain unchanged. WHO now recommends a single, low dose (0.25 mg\/kg bw) to reduce onward transmission of <em>P. falciparum<\/em> malaria in programmes to eliminate <em>P. falciparum<\/em> malaria and in areas threatened by resistance of <em>P. falciparum<\/em> to artemisinins (24). This lower dose is safer and was considered to be as effective in reducing transmissibility on the basis of the limited available data from assessments of direct transmission blocking in mosquito feeding studies, which is considered therapeutically more relevant than gametocyte clearance (1, 25\u201327). The feasibility of achieving this lower dosage in young children would be enhanced by the availability of a pre-qualified 3.75-mg primaquine tablet.<\/p>&#13;\n&#13;\n<p><strong>References<\/strong><\/p>&#13;\n&#13;\n<p>1. Recht J, Ashley EA, White NJ. Safety of 8-aminoquinoline antimalarial medicines. Geneva: World Health Organization; 2014 (<a href=\"https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241506977\/en\/\">http:\/\/www.who.int\/ malaria\/publications\/atoz\/9789241506977\/en\/<\/a>).<\/p>&#13;\n&#13;\n<p>2. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75:402\u201315.<\/p>&#13;\n&#13;\n<p>3. Hiebsch RR, Raub TJ, Wattenberg BW. Primaquine blocks transport by inhibiting the formation of functional transport vesicles. Studies in a cell- free assay of protein transport through the Golgi apparatus. J Biol Chem 1991;266:20323\u20138.<\/p>&#13;\n&#13;\n<p>4. Mihaly GW, Ward SA, Edwards G, Nicholl DD, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br J Clin Pharmacol 1985;19:745\u201350.<\/p>&#13;\n&#13;\n<p>5. Ganesan S, Tekwani BL, Sahu R, Tripathi LM, Walker LA. Cytochrome P(450)- dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol 2009;241:14\u201322.<\/p>&#13;\n&#13;\n<p>6. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J 2013;12:212.<\/p>&#13;\n&#13;\n<p>7. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. An open-label crossover study of primaquine and dihydroartemisinin\u2013piperaquine pharmacokinetics in healthy adult Thai subjects. Antimicrob Agents Chemother 2014;58:7340\u20136.<\/p>&#13;\n&#13;\n<p>8. Clark AM, Baker JK, McChesney JD. Excretion, distribution, and metabolism of primaquine in rats. J Pharm Sci 1984;73:502\u20136.<\/p>&#13;\n&#13;\n<p>9. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, et al. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Am J Trop Med Hyg 2009;81:747\u201353.<\/p>&#13;\n&#13;\n<p>10. Cuong BT, Binh VQ, Dai B, Duy DN, Lovell CM, Rieckmann KH, et al. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects? Br J Clin Pharmacol 2006;61:682\u20139.<\/p>&#13;\n&#13;\n<p>11. Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD. Lack of sex effect on the pharmacokinetics of primaquine. Am J Trop Med Hyg 2006;74:951\u20132.<\/p>&#13;\n&#13;\n<p>12. Kulkarni SP, Shah SR, Kadam PP, Sridharan K, Hase NK, Shetty PP, et al. Pharmacokinetics of single-dose primaquine in patients with chronic kidney dysfunction. Indian J Pharmacol 2013;45:330\u20133.<\/p>&#13;\n&#13;\n<p>13. Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TM, et al. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol 1993;35:193\u20138.<\/p>&#13;\n&#13;\n<p>14. Fletcher KA, Evans DA, Gilles HM, Greaves J, Bunnag D, Harinasuta T. Studies on the pharmacokinetics of primaquine. Bull World Health Organ 1981;59:407\u201312.<\/p>&#13;\n&#13;\n<p>15. Kim YR, Kuh HJ, Kim MY, Kim YS, Chung WC, Kim SI, et al. Pharmacokinetics of primaquine and carboxyprimaquine in Korean patients with vivax malaria. Arch Pharm Res 2004;27:576\u201380.<\/p>&#13;\n&#13;\n<p>16. Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, Chanthavanich P, et al. Pharmacokinetics of primaquine in man. II. Comparison of acute vs chronic dosage in Thai subjects. Br J Clin Pharmacol 1985;19:751\u20135.<\/p>&#13;\n&#13;\n<p>17. Pukrittayakamee S, Tarning J, Jittamala P, Charunwatthana P, Lawpoolsri S, Lee SJ, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58:3354\u20139.<\/p>&#13;\n&#13;\n<p>18. Moore BR, Salman S, Benjamin J, Page-Sharp M, Robinson LJ, Waita E, et al. Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother 2014;58:432\u20139.<\/p>&#13;\n&#13;\n<p>19. Betuela I, Bassat Q, Kiniboro B, Robinson LJ, Rosanas-Urgell A, Stanisic D, et al. Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrob Agents Chemother 2012;56:2146\u20139.<\/p>&#13;\n&#13;\n<p>20. Ebringer A, Heathcote G, Baker J, Waller M, Shanks GD, Edstein MD. Evaluation of the safety and tolerability of a short higher-dose primaquine regimen for presumptive anti-relapse therapy in healthy subjects. Trans R Soc Trop Med Hyg 2011;105:568\u201373.<\/p>&#13;\n&#13;\n<p>21. Silachamroon U, Krudsood S, Treeprasertsuk S, Wilairatana P, Chalearmrult K, Mint HY, et al. Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg 2003;69:14\u20138.<\/p>&#13;\n&#13;\n<p>22. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a <em>Plasmodium falciparum<\/em> gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:418.<\/p>&#13;\n&#13;\n<p>23. Howes RE, Battle KE, Satyagraha AW, Baird JK, Hay SI. G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol 2013;81:133\u2013201.<\/p>&#13;\n&#13;\n<p>24. Single dose primaquine as a gametocytocide in <em>Plasmodium falciparum<\/em> malaria; updated WHO policy recommendation. Geneva: World Health Organization; 2012 (<a href=\"https:\/\/www.who.int\/malaria\/publications\/atoz\/who_pq_policy_recommendation\/en\/\">http:\/\/www.who.int\/malaria\/publications\/atoz\/who_ pq_policy_recommendation\/en\/<\/a>).<\/p>&#13;\n&#13;\n<p>25. White NJ. Primaquine to prevent transmission of falciparum malaria. Lancet Infect Dis 2013;13:175\u201381.<\/p>&#13;\n&#13;\n<p>26. White NJ, Qiao LG, Qi G, Luzzatto L. Rationale for recommending a lower dose of primaquine as a <em>Plasmodium falciparum<\/em> gametocytocide in populations where G6PD deficiency is common. Malar J 2012;11:e418.<\/p>&#13;\n&#13;\n<p>27. Ashley EA, Recht J, White NJ. Primaquine; the risks and the benefits. Malar J 2014;13:418.<\/p>&#13;\n","title":"A5.11 Primaquine","nid":514,"vid":1474,"created":1573123719,"changed":1573197741,"field_content_type":{"tid":2,"name":"Content","class":"content"},"field_operational_":[{"field_image":"","field_link":"","field_title":null}],"field_references":null}